Related Experiment Videos
[Isolation of recombinant interleukin-3 produced by E. coli]
Bioorganicheskaia Khimiia
|December 1, 1991
Summary
Synthetically engineered human interleukin-3 (hIL3) was produced in E. coli, achieving high yields. An efficient purification method yielded biologically active hIL3, demonstrating its potential therapeutic applications.
Area of Science:
- Biotechnology
- Molecular Biology
- Protein Engineering
Background:
- Human interleukin-3 (hIL3) is a crucial cytokine for hematopoiesis and immune responses.
- Efficient and scalable production of recombinant hIL3 is essential for therapeutic and research applications.
Purpose of the Study:
- To develop a cost-effective method for high-level expression and purification of recombinant human interleukin-3 (hIL3) in E. coli.
- To characterize the biological activity of the purified recombinant hIL3.
Main Methods:
- Gene synthesis and cloning of hIL3 into the pTE2IL3 plasmid.
- Expression in E. coli under the control of fd PVIII promoter and T7 gene 10 translational enhancer.
- Inclusion body solubilization, renaturation, and single-step purification using chromatography.
Main Results:
- Recombinant hIL3 accumulated to 30-40% of total cell protein in E. coli inclusion bodies.
- An effective isolation procedure yielded 34 mg of purified hIL3 per gram of wet cells.
- The purified hIL3 demonstrated specific biological activity.
Conclusions:
- A robust and efficient system for producing biologically active recombinant hIL3 in E. coli has been established.
- The developed purification protocol is suitable for large-scale production of therapeutic-grade hIL3.